MF Researcher Database

Researcher Database

Advance

Ishida Hiroo

■FacultyMedical Oncology
■PositionAssociate Professor
Last Updated :2025/05/15

Researcher

基本情報

Profile and Settings

  • 氏名

    Ishida Hiroo

Affiliation

  • Medical Oncology, Associate Professor

Location

  • Fujigaoka Hospital

Degree

  • Doctor of Medical Science, Showa University, Mar. 2007

Achievements

Published Papers

  • Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan., Tomura Kazuki;Sakamaki Hiroyuki;Nawata Shuichi;Ishida Hiroo;Tanaka Katsumi;Kogo Mari, International journal of clinical pharmacy, 47(2):304 - 313, Apr. 2025, Peer-reviewed, DOI:10.1007/s11096-024-01826-7
  • Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study, Hiroo Ishida; Yu Sunakawa; Yasuhiro Kodera; Kazuhiro Yoshida; Mitsugu Kochi; Yoshihiro Kakeji; Takeshi Sano; Masahiro Takeuchi; Wataru Ichikawa; Masashi Fujii, European Journal of Cancer, 219, Mar. 2025, Peer-reviewed, DOI:10.1016/j.ejca.2025.115322
  • Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer., Nakayama Hana;Ishida Hiroo;Iidaka Masanori;Kato Shoko;Nakatani Kei;Nakayama Akihiro;Noguchi Toshihiro;Nishihara Shigetoshi;Oikawa Shu;Usami Tomono;Mitsui Yuta;Ishii Y U;Toshima Hirokazu;Kobayashi Kouji;Murase Remi;Matsumoto Natsumi;Suzuki Kosuke;Shimada Ken;Yoshida Hitoshi;Fujita Ken-Ichi, Anticancer research, 44(11):5023 - 5033, Nov. 2024, Peer-reviewed, DOI:10.21873/anticanres.17326
  • Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reactions and survival of regorafenib in Japanese patients with colorectal cancer, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, Cancer Chemotherapy and Pharmacology, 94(1):57 - 66, Jul. 2024, Peer-reviewed
  • Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer., Fujita KI, Matsumoto N, Murase R, Takeshima K, Ishida H, Kubota Y, Clin Transl Sci, 16(10):1741 - 1747, Oct. 2023, Peer-reviewed
  • A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer, Yukitaka Shibata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Ken-Ichi Fujita, Cancer Chemother Pharmacol, Aug. 2023, Peer-reviewed, DOI:doi.org/10.1007/s00280-023-04584-x
  • A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis, Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N, Ther Adv Med Oncol, 14:17588359221142786, Dec. 2022, Peer-reviewed
  • Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study., Nio Yuta;Ishida Hiroo;Matsumoto Natsumi;Kusumoto Sojiro;Kubota Yutaro;Tsunoda Takuya;Sasaki Yasutsuna;Fujita Ken-Ichi, BMC pulmonary medicine, 22(1), Nov. 2022, Peer-reviewed
  • Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)., Naka G, Yokoyama T, Usui K, Ishida H, Kishi K, Uemura K, Ohashi Y, Kunitoh H., Jpn J Clin Oncol, 52(7):791 - 794, Jul. 2022, Peer-reviewed
  • Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study), Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N, Ther Adv Med Oncol, 14:17588359221116603, Jul. 2022, Peer-reviewed
  • The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure, SUGANUMA Hiromitsu;KUSUMOTO Sojiro;MANABE Ryo;KISHINO Yasunari;ENDO Tetsuya;ANDO Koichi;ISHIDA Hiroo;HORIIKE Atsushi;TANAKA Akihiko;TAKEI Hidefumi;YAMOCHI Toshiko;TSUNODA Takuya;SAGARA Hironori, Showa Univ J Med Sci, 34(2):64 - 77, Jun. 2022, Peer-reviewed, DOI:https://doi.org/10.15369/sujms.34.64
  • Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer., Arai J, Otoyama Y, Fujita KI, Goto K, Tojo M, Katagiri A, Nozawa H, Kubota Y, Takahashi T, Ishida H, Tsunoda T, Matsumoto N, Ogawa K, Nakagawa R, Muroyama R, Kato N, Yoshida H., BMC Cancer, 22(1):428, Apr. 2022, Peer-reviewed
  • Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer., Jun Arai; Yumi Otoyama; Ken-Ichi Fujita; Kaku Goto; Masayuki Tojo; Atsushi Katagiri; Hisako Nozawa; Yutaro Kubota; Takehiro Takahashi; Hiroo Ishida; Takuya Tsunoda; Natsumi Matsumoto; Keita Ogawa; Ryo Nakagawa; Ryosuke Muroyama; Naoya Kato; Hitoshi Yoshida, BMC cancer, 22(1):428 - 428, Apr. 2022, Peer-reviewed
  • A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report., Kazuyuki Hamada; Kiyoshi Yoshimura; Kazuhiko Oshinomi; Yuya Hirasawa; Hirotsugu Ariizumi; Ryotaro Ohkuma; Midori Shida; Yutaro Kubota; Hiroto Matsui; Tomoyuki Ishiguro; Takehiko Sambe; Hiroo Ishida; Atsushi Horiike; Satoshi Wada; Sanju Iwamoto; Naoki Uchida; Yoshio Ogawa; Shinichi Kobayashi; Takuya Tsunoda, Medicine, 101(2):e28339, Jan. 2022, Peer-reviewed
  • Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure., TSUBOYA Ayako;KUBOTA Yutaro;ISHIDA Hiroo;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;SASAKI Yasutsuna;MATSUMOTO Natsumi;KONDO Yusuke;TOMODA Yukana;KUSUHARA Hiroyuki;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 88(3):543 - 553, Sep. 2021, Peer-reviewed
  • Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients., KATAYAMA Koki;NAKASHIMA Shimon;ISHIDA Hiroo;KUBOTA Yutaro;NAKANO Masataka;FUKAMI Tatsuki;SASAKI Yasutsuna;FUJITA Ken-ichi;NAKAJIMA Miki, Non-coding RNA Res, 6(3):123 - 129, Jun. 2021, Peer-reviewed
  • Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer, Yutaro Kubota; Kiyoshi Yoshimura; Kazuyuki Hamada; Yuya Hirasawa; Midori Shida; Makoto Taniguchi; Hiroto Matsui; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Norihiro Suzuki; Ryotaro Ohkuma; Takehiko Sambe; Hiroo Ishida; Atsushi Horiike; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Shinichi Kobayashi; Takuya Tsunoda, IN VIVO, 35(3):1865 - 1875, May 2021, Peer-reviewed
  • A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study), TANZAWA Shigeru;USHIJIMA Sunao;SHIBATA Kazuhiko;SHIBAYAMA Takuo;BESSHO Akihiro;KAIRA Kyoichi;MISUMI Toshihiro;SHIRAISHI Kenshiro;MATSUTANI Noriyuki;TANAKA Hisashi;INABA Megumi;HARUYAMA Terunobu;NAKAMURA Junya;KISHIKAWA Takayuki;NAKASHIMA Masanao;IWASA Keiichi;FUJIWARA Keiichi;KOHYAMA Tadashi;KUYAMA Shoichi;MIYAZAWA Naoki;NAKAMURA Tomomi;MIYAWAKI Hiroshi;ISHIDA Hiroo;ODA Naohiro;ISHIKAWA Nobuhisa;MORINAGA Ryotaro;KUSAKA Kei;FUJIMOTO Nobukazu;YOKOYAMA Toshihide;GEMBA Kenichi;TSUDA Takeshi;NAKAGAWA Hideyuki;ONO Hirotaka;SHIMIZU Tetsuo;NAKAMURA Morio;KUSUMOTO Sojiro;HAYASHI Ryuji;SHIRASAKI Hiroki;OCHI Nobuaki;AOE Keisuke;KANAJI Nobuhiro;KASHIWABARA Kosuke;INOUE Hiroshi;SEKI Nobuhiko, Ther Adv Med Oncol ., 13:1758835921998588, Feb. 2021, Peer-reviewed
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Hirasawa Yuya;Yoshimura Kiyoshi;Matsui Hiroto;Kubota Yutaro;Ishida Hiroo;Arai Jun;Sakaki Masashi;Oguro Nao;Shida Midori;Taniguchi Makoto;Hamada Kazuyuki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Ohkuma Ryotaro;Sambe Takehiko;Horiike Atsushi;Imamura Chiyo K;Shiozawa Eisuke;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Tate Genshu;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 100(23):e25774, 2021, Peer-reviewed
  • Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy., MINATOGAWA H;IZAWA N;KAWAGUCHI T;MIYAJI T;SHIMOMURA K;KAZUNORI H;IIHARA H;OHNO Y;INADA Y;ARIOKA H;MORITA H;HIDA N;SUGAWARA M;KATADA C;NAWATA Shuichi;ISHIDA Hiroo;TSUBOYA A;TSUDA T;YAMAGUCHI T;NAKAJIMA TE, BMJ Open, 10(12):e041737, Dec. 2020, Peer-reviewed
  • Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients., Yutaro Kubota; Ken-Ichi Fujita; Takehiro Takahashi; Yu Sunakawa; Hiroo Ishida; Kazuyuki Hamada; Wataru Ichikawa; Takuya Tsunoda; Kazuhiro Shimada; Yusuke Masuo; Yukio Kato; Yasutsuna Sasaki, Clinical pharmacology and therapeutics, 108(3):586 - 595, Sep. 2020, Peer-reviewed
  • Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis., TOSHIMA Hirokazu;HISAMATSU Atushi;KOBAYASHI Koji;ISHIDA Hiroo;SHIAMADA Ken., Cancers, 12(7):1711, Jun. 2020, Peer-reviewed
  • Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients., Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Masae Sekido; Ryotaro Ohkuma; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Takuya Tsunoda; Toshikazu Ikusue; Kouji Kobayashi; Atsushi Hisamatsu; Hirokazu Toshima; Ken Shimada; Ken-Ichi Fujita, Cancer chemotherapy and pharmacology, 85(6):1119 - 1128, Jun. 2020, Peer-reviewed
  • Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel., Daiki Mori; Hiroo Ishida; Tadahaya Mizuno; Sojiro Kusumoto; Yusuke Kondo; Saki Izumi; Genki Nakata; Yoshitane Nozaki; Kazuya Maeda; Yasutsuna Sasaki; Ken-Ichi Fujita; Hiroyuki Kusuhara, Drug metabolism and disposition: the biological fate of chemicals, 48(5):387 - 394, May 2020, Peer-reviewed
  • High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, Jan. 2020, Peer-reviewed
  • High-throughput method to analyze tegafur and 5-fluorouracil in human tears and plasma using hydrophilic interaction liquid chromatography/tandem mass spectrometry., Ritsuko Shiokawa; Xiao-Pen Lee; Miho Yamada; Masaya Fujishiro; Hiroshi Sakamaki; Chika Hasegawa; Hiroo Ishida; Kenichiro Ikeda; Ken-Ichi Fujita; Shigehiro Iwabuchi; Hidetoshi Onda; Takeshi Kumazawa; Yasutsuna Sasaki; Keizo Sato; Takaaki Matsuyama, Rapid communications in mass spectrometry : RCM, 33(24):1906 - 1914, Dec. 2019, Peer-reviewed
  • VEGF Inhibitors Do Not Increase D-dimer Levels in Colorectal Cancer Patients Without Venous Thromboembolism: A Retrospective Non-inferiority Analysis., Toshima H;Ikusue T;Hisamatsu A;Kobayashi K;Ishida H;Shimada K, In Vivo, 33(6):2117 - 2123, Dec. 2019, Peer-reviewed
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, Sep. 2019, Peer-reviewed
  • Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)., Usui K;Yokoyama T;Naka G;ISHIDA Hiroo;Kishi K;Uemura K;Ohashi Y;Kunitoh H, Jpn J Clin Oncol, 49(6):554 - 558, Jun. 2019, Peer-reviewed
  • Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil, SEKIDO Masae;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKAHASHI Takehiro;OHKUMA Ryotaro;TSUNODA Takuya;ISHIKAWA Fumihiro;SHIBANUMA Motoko;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 83(6):1127 - 1135, Jun. 2019, Peer-reviewed
  • Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil, SEKIDO Masae;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKAHASHI Takehiro;OHKUMA Ryotaro;TSUNODA Takuya;ISHIKAWA Fumihiro;SHIBANUMA Motoko;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 83(6):1127 - 1135, Jun. 2019, Peer-reviewed
  • Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38, IWASE Mariko;FUJITA Ken-ichi;NISHIMURA Yuki;SEBA Natsumi;MASUO Yusuke;ISHIDA Hiroo;KATO Yukio;KIUCHI Yuji, Cancer Chemother Pharmacol, 83(5):993 - 998, May 2019, Peer-reviewed
  • Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure, FUJITA Ken-ichi;MATSUMOTO Natsumi;ISHIDA Hiroo;KUBOTA Yutaro;IWAI Shinichi;SHIBANUMA Motoko;KATO Yukio, Curr Drug Metab, 20(5):361 - 376, Mar. 2019, Peer-reviewed
  • Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer., TSUBOYA Ayako;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, Int J Clin Oncol, 24(2):222 - 230, Feb. 2019, Peer-reviewed
  • Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan., SATOH Etsuko;SASAKI Yasutsuna;OHKUMA Ryotaro;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;HAMADA Kazuyuki;KIUCHI Yuji;TSUNODA Takuya, Cancer Sci, 109(12):3896 - 3901, Dec. 2018
  • Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib, Waleed Elsayed Ahmed Ellawatty; Yusuke Masuo; Ken-Ichi Fujita; Erina Yamazaki; Hiroo Ishida; Hiroshi Arakawa; Noritaka Nakamichi; Ramadan Abdelwahed; Yasutsuna Sasaki; Yukio Kato, Drug Metabolism and Disposition, 46(1):33 - 40, Jan. 2018, Peer-reviewed
  • Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation, Toshimitsu Yamaoka; Tohru Ohmori; Motoi Ohba; Satoru Arata; Yasunori Murata; Sojiro Kusumoto; Koichi Ando; Hiroo Ishida; Tsukasa Ohnishi; Yasutsuna Sasaki, MOLECULAR CANCER RESEARCH, 15(7):915 - 928, Jul. 2017, Peer-reviewed
  • Peripancreatic Tuberculous Lymphadenitis Diagnosed via Endoscopic Ultrasound-guided Fine-needle Aspiration and Polymerase Chain Reaction, Arai Jun;Kitamura Katsuya;Yamamiya Akira;Ishii Yu;Nomoto Tomohiro;Honma Tadashi;Ishida Hiroo;Shiozawa Eisuke;Takimoto Masafumi;Yoshida Hitoshi, Internal Medicine, 56(9):1049 - 1052, May 2017, Peer-reviewed, DOI:10.2169/internalmedicine.56.7509
  • Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology, Ken-ichi Fujita; Hiroo Ishida; Yutaro Kubota; Yasutsuna Sasaki, CURRENT DRUG METABOLISM, 18(3):186 - 198, Mar. 2017, Peer-reviewed
  • Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation, Toshimitsu Yamaoka; Tohru Ohmori; Motoi Ohba; Satoru Arata; Yasunari Kishino; Yasunori Murata; Sojiro Kusumoto; Hiroo Ishida; Takao Shirai; Takashi Hirose; Tsukasa Ohnishi; Yasutsuna Sasaki, MOLECULAR CANCER THERAPEUTICS, 15(12):3040 - 3054, Dec. 2016, Peer-reviewed
  • Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan., Takata Kosuke;Fujita Ken-Ichi;Kubota Yutaro;Ishida Hiroo;Ichikawa Wataru;Shimada Ken;Sekikawa Takashi;Taki-Takemoto Iori;Kamei Daisuke;Iwai Shinichi;Sasaki Yasutsuna, Journal of pharmaceutical health care and sciences, 2(30):1 - 9, Nov. 2016, Peer-reviewed
  • HILIC-MS/MS法によるヒト涙液中tegafurおよび5-fluorouracilの高感度分析法, 小渕　律子;李　暁鵬;石田　博雄;熊澤　武志;池田　賢一郎;藤城　雅也;藤田　健一;佐藤　淳一;澤口　聡子;高橋　春男;佐藤　啓造, 昭和学士会雑誌, 76(3):299 - 307, Jun. 2016, Peer-reviewed
  • Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer, Takashi Hirose; Ken-ichi Fujita; Sojiro Kusumoto; Yasunari Oki; Yasunori Murata; Tomohide Sugiyama; Hiroo Ishida; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Kentaro Okuda; Tohru Ohmori; Yasutsuna Sasaki, LUNG CANCER, 93:69 - 76, Mar. 2016, Peer-reviewed
  • Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan., Takata K; Fujita KI; Kubota Y; Ishida H; Ichikawa W; Shimada K; Sekikawa T; Taki-Takemoto I; Kamei D; Iwai S; Sasaki Y, Journal of pharmaceutical health care and sciences, 2:30 - 30, 2016, Peer-reviewed
  • A Case of Drug Induced Lung Injury Considered to Be Caused by a Supplement "Nin-niku Ran-ou (Garlic and Egg Yolk) ", Suzuki Shintaro; Tanaka Akihiko; Kishino-Oki Yasunari; Murata Yasunori; Kusumoto Sojiro; Ishida Hiroo; Ando Koichi; Shirai Takao; Ohnishi Tsukasa; Sagara Hironori; Takimoto Masafumi, The Journal of the Japan Society for Respiratory Endoscopy, 38(2):118 - 124, 2016, Peer-reviewed
  • Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;SASAKI Yasutsuna, World J Gastroenterol, 21(43):12234 - 12248, Nov. 2015, Peer-reviewed
  • A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer, Ken-ichi Fujita; Etsuko Yoshino; Kaori Kawara; Kazuya Maeda; Hiroyuki Kusuhara; Yuichi Sugiyama; Taro Yokoyama; Toshikado Kaneta; Hiroo Ishida; Yasutsuna Sasaki, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 76(4):793 - 801, Oct. 2015, Peer-reviewed, DOI:10.1007/s00280-015-2844-2
  • Crizotinib-induced pancreatic pseudocyst: A novel adverse event, Hiroo Ishida; Wataru Ichikawa; Yasutsuna Sasaki, BMJ Case Reports, 2015:1 - 3, Sep. 2015, Peer-reviewed, DOI:10.1136/bcr-2015-211556
  • Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?, Yasutsuna Sasaki; Kazuyuki Hamada; Toshikado Kaneta; Takehiro Takahashi; Yutaro Kubota; Hiroo Ishida; Wataru Ichikawa, CANCER SCIENCE, 106(8):1100 - 1100, Aug. 2015
  • A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors., SASAKI Yasutsuna;MIWA Keisuke;YAMASHITA Keishi;SUNAKAWA Yu;SHIMADA Ken;ISHIDA Hiroo;HASEGAWA Kosei;FUJIWARA Keiichi;KODAIRA Makoto;FUJIWARA Yasuhiro;NAMIKI Masayuki;MATSUDA Minami;TAKEUCHI Yutaka;KATSUMATA Noriyuki, Invest New Drugs, 33(2):332 - 340, Apr. 2015, Peer-reviewed
  • A phase I study of farletuzumab, a humanized anti-folate receptor alpha monoclonal antibody, in patients with solid tumors, Yasutsuna Sasaki; Keisuke Miwa; Keishi Yamashita; Yu Sunakawa; Ken Shimada; Hiroo Ishida; Kosei Hasegawa; Keiichi Fujiwara; Makoto Kodaira; Yasuhiro Fujiwara; Masayuki Namiki; Minami Matsuda; Yutaka Takeuchi; Noriyuki Katsumata, INVESTIGATIONAL NEW DRUGS, 33(2):332 - 340, Apr. 2015, Peer-reviewed
  • Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer., Koko Ishida; Takashi Hirose; Junichi Yokouchi; Yasunari Oki; Sojiro Kusumoto; Tomohide Sugiyama; Hiroo Ishida; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Tsukasa Ohnishi; Tohru Ohmori; Yoshikazu Kagami, Molecular and clinical oncology, 2(3):405 - 410, May 2014, Peer-reviewed
  • Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors, Megumi Inada-Inoue; Yuichi Ando; Kenji Kawada; Ayako Mitsuma; Masataka Sawaki; Taro Yokoyama; Yu Sunakawa; Hiroo Ishida; Kazuhiro Araki; Keishi Yamashita; Keiko Mizuno; Fumio Nagashima; Akiko Takekura; Kazuo Nagamatsu; Yasutsuna Sasaki, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 73(4):673 - 683, Apr. 2014, Peer-reviewed
  • Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer, Tetsuya Sasaki; Ken-ichi Fujita; Yu Sunakawa; Hiroo Ishida; Keishi Yamashita; Keisuke Miwa; Shigehira Saji; Yasuhisa Kato; Yasutsuna Sasaki, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 18(4):735 - 742, Aug. 2013, Peer-reviewed
  • Evaluation of the Safety and Efficacy of Combination Chemotherapy with Vinorelbine and Platinum Agents for Patients with Non-small Cell Lung Cancer with Interstitial Lung Disease, Kentaro Okuda; Takashi Hirose; Yasunari Oki; Yasunori Murata; Sojiro Kusumoto; Tomohide Sugiyama; Hiroo Ishida; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Tsukasa Ohnishi; Tohru Ohmori, ANTICANCER RESEARCH, 32(12):5475 - 5480, Dec. 2012, Peer-reviewed
  • 進行再発非小細胞肺癌に対するセカンドライン化学療法の検討, 白井　崇生;廣瀬　敬;村田　泰規;大木　康成;楠本　壮二郎;杉山　智英;石田　博雄;中嶌　賢尚;大西　司;山岡　利光;大森　亨;奥田　健太郎, 昭和医学会雑誌, 72(4):446 - 452, Aug. 2012, Peer-reviewed, DOI:10.14930/jsma.72.446
  • Association of ABCC2 Genotype with Efficacy of First-line FOLFIRI in Japanese Patients with Advanced Colorectal Cancer, Yuko Akiyama; Ken-ichi Fujita; Hiroo Ishida; Yu Sunakawa; Keishi Yamashita; Kaori Kawara; Keisuke Miwa; Shigehira Saji; Yasutsuna Sasaki, DRUG METABOLISM AND PHARMACOKINETICS, 27(3):325 - 335, Jun. 2012, Peer-reviewed
  • Relationship of Circulating Tumor Cells to the Effectiveness of Cytotoxic Chemotherapy in Patients With Metastatic Non-Small-Cell Lung Cancer, Takashi Hirose; Yasunori Murata; Yasunari Oki; Tomohide Sugiyama; Sojiro Kusumoto; Hiroo Ishida; Takao Shirai; Masano Nakashima; Toshimitsu Yamaoka; Kentaro Okuda; Tsukasa Ohnishi; Tohru Ohmori, ONCOLOGY RESEARCH, 20(2月3日):131 - 137, Feb. 2012, Peer-reviewed
  • A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1, *1/*6 or *1/*28, Yu Sunakawa; Ken-ichi Fujita; Wataru Ichikawa; Hiroo Ishida; Keishi Yamashita; Kazuhiro Araki; Keisuke Miwa; Kaori Kawara; Yuko Akiyama; Wataru Yamamoto; Fumio Nagashima; Shigehira Saji; Yasutsuna Sasaki, ONCOLOGY, 82(4):242 - 248, 2012, Peer-reviewed
  • UGT1A1*1/*28 and*1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer, Yu Sunakawa; Wataru Ichikawa; Ken-ichi Fujita; Fumio Nagashima; Hiroo Ishida; Keishi Yamashita; Keiko Mizuno; Keisuke Miwa; Kaori Kawara; Yuko Akiyama; Kazuhiro Araki; Wataru Yamamoto; Toshimichi Miya; Masaru Narabayashi; Yuichi Ando; Takashi Hirose; Shigehira Saji; Yasutsuna Sasaki, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 68(2):279 - 284, Aug. 2011, Peer-reviewed
  • Regimen Selection for First-line FOLFIRI and FOLFOX Based on UGT1A1 Genotype and Physical Background is Feasible in Japanese Patients with Advanced Colorectal Cancer, Hiroo Ishida; Ken-ichi Fujita; Yuko Akiyama; Yu Sunakawa; Keishi Yamashita; Keiko Mizuno; Keisuke Miwa; Kaori Kawara; Wataru Ichikawa; Yuichi Ando; Shigehira Saji; Yasutsuna Sasaki, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41(5):617 - 623, May 2011, Peer-reviewed
  • Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure, Ken-ichi Fujita; Yu Sunakawa; Keisuke Miwa; Yuko Akiyama; Minako Sugiyama; Kaori Kawara; Hiroo Ishida; Keishi Yamashita; Keiko Mizuno; Shigehira Saji; Wataru Ichikawa; Wataru Yamamoto; Fumio Nagashima; Toshimichi Miya; Masaru Narabayashi; Yuichi Ando; Takashi Hirose; Yasutsuna Sasaki, DRUG METABOLISM AND DISPOSITION, 39(2):161 - 164, Feb. 2011, Peer-reviewed
  • Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer, Takashi Hirose; Ken-Ichi Fujita; Kazuko Nishimura; Hiroo Ishida; Keishi Yamashita; Yu Sunakawa; Keiko Mizuno; Keisuke Miwa; Fumio Nagashima; Yusuke Tanigawara; Mitsuru Adachi; Yasutsuna Sasaki, ONCOLOGY REPORTS, 24(2):529 - 536, Aug. 2010, Peer-reviewed
  • Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX6 for Metastatic Colorectal Cancer, Hidetomo Ajima; Hiroyasu Ogata; Ken-ichi Fujita; Keisuke Miwa; Yu Sunakawa; Keiko Mizuno; Hiroo Ishida; Keishi Yamashita; Hirofumi Nakayama; Kaori Kawara; Harumi Takahashi; Yasutsuna Sasaki, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40(7):634 - 638, Jul. 2010, Peer-reviewed
  • Combination Effect between Bortezomib and Tumor Necrosis Factor alpha on Gefitinib-resistant Non-small Cell Lung Cancer Cell Lines, Sojiro Kusumoto; Tomohide Sugiyama; Koichi Ando; Takamichi Hosaka; Hiroo Ishida; Takao Shirai; Toshimitsu Yamaoka; Kentaro Okuda; Takashi Hirose; Tsukasa Ohnishi; Fumiko Inoue; Tomoko Kanome; Tsuyoki Kadofuku; Nagahiro Saijo; Mitsuru Adachii; Tohru Ohmori, ANTICANCER RESEARCH, 29(6):2315 - 2322, Jun. 2009, Peer-reviewed
  • Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI), Ken-ichi Fujita; Fumio Nagashima; Wataru Yamamoto; Hisashi Endo; Yu Sunakawa; Keishi Yamashita; Hiroo Ishida; Keiko Mizuno; Mototsugu Matsunaga; Kazuhiro Araki; Ryuhei Tanaka; Wataru Ichikawa; Toshimichi Miya; Masaru Narabayashi; Yuko Akiyama; Kaori Kawara; Yuichi Ando; Yasutsuna Sasaki, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 31(11):2137 - 2142, Nov. 2008, Peer-reviewed
  • Patient satisfaction with sedation for flexible bronchoscopy, Takashi Hirose; Kentaro Okuda; Hiroo Ishida; Tomohide Sugiyama; Sojiro Kusumoto; Masanao Nakashima; Toshimitsu Yamaoka; Mitsuru Adachi, RESPIROLOGY, 13(5):722 - 727, Jul. 2008, Peer-reviewed
  • Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer, Kentaro Okuda; Takashi Hirose; Hiroo Ishida; Sojiro Kusumoto; Tomohide Sugiyama; Kohichi Ando; Takao Shirai; Tsukasa Ohnishi; Naoya Horichi; Tohru Ohmori; Mitsuru Adachi, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 61(5):829 - 835, Apr. 2008, Peer-reviewed
  • Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl, Takamichi Hosaka; Fumiko Inoue; Koichi Ando; Hiroo Ishida; Sojiro Kusumoto; Tomohide Sugiyama; Takao Shirai; Kentaro Okuda; Takashi Hirose; Tsukasa Ohnishi; Naoya Horichi; Nagahiro Saijo; Mitsuru Adachi; Toshio Nakadate; Toshio Kuroki; Tohru Ohmori, ANTICANCER RESEARCH, 27(4B):2253 - 2263, Jul. 2007, Peer-reviewed
  • Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer, Takashi Hirose; Takao Shirai; Hiroo Ishida; Kohichi Ando; Tomohide Sugiyama; Sojiro Kusumoto; Takamichi Hosaka; Masanao Nakashima; Tohru Ohmori; Mitsuru Adachi, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 60(2):267 - 274, Jul. 2007, Peer-reviewed
  • Comparison of Biweekly and Triweekly Therapy with Docetaxel and Irinotecan for Refractory or Relapsed Advanced Non-small-cell Lung cancer, ISHIDA Hiroo; HIROSE Takashi; SHIRAI Takao; OKUDA Kentaro; SUGIYAMA Tomohide; KUSUMOTO Sojiro; HOSAKA Takamichi; ANDO Kohichi; NAKASHIMA Masanao; YAMAOKA Toshimitsu; OHNISHI Tsukasa; HORICHI Naoya; OHMORI Tohru; ADACHI Mitsuru, The Showa University Journal of Medical Sciences, 19(2):103 - 111, 2007, Peer-reviewed
  • Gefitinib Cytotoxicity in Non-small Cell Lung Cancer Cells is Enhanced by Low Dose Cisplatin Due to Ligand-independent EGFR Autophosphorylation, HOSAKA Takamichi; OHMORI Tohru; ANDO Koichi; ISHIDA Hiroo; KUSUMOTO Sojiro; SUGIYAMA Tomohide; SHIRAI Takao; OKUDA Kentaro; HIROSE Takashi; OHNISHI Tsukasa; HORICHI Naoya; INOUE Fumiko; SAUO Nagahiro; KUROKI Toshio; NAKADATE Toshio; ADACHI Mitsuru, The Showa University Journal of Medical Sciences, 19(3):155 - 164, 2007, Peer-reviewed
  • The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer, T Hirose; Y Mizutani; T Ohmori; H Ishida; T Hosaka; K Ando; T Shirai; K Okuda; T Ohnishi; N Horichi; H Kubota; M Adachi, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 58(3):361 - 367, Sep. 2006, Peer-reviewed
  • Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer, T Shirai; T Hirose; M Noda; K Ando; H Lshida; T Hosaka; T Ozawa; K Okuda; T Ohnishi; T Ohmori; N Horichi; M Adachi, LUNG CANCER, 52(2):181 - 187, May 2006, Peer-reviewed
  • Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib, K Ando; T Ohmori; F Inoue; T Kadofuku; T Hosaka; H Ishida; T Shirai; K Okuda; T Hirose; N Horichi; K Nishio; N Saijo; M Adachi; A Kuroki, CLINICAL CANCER RESEARCH, 11(24):8872 - 8879, Dec. 2005, Peer-reviewed
  • 当院に於ける包括的呼吸器リハビリテーション, 大西 司; 奥田 健太郎; 保阪 隆道; 石田 博雄; 安藤 浩一; 白井 崇生; 廣瀬 敬; 堀地 直也; 足立 満; 城井 義隆; 川手 信行; 水間 正澄, 昭和医学会雑誌, 64(6):524 - 525, Dec. 2004, Peer-reviewed
  • Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer, T Hirose; N Horichi; T Ohmori; K Ogura; T Hosaka; K Ando; H Ishida; H Noguchi; M Adachi, LUNG CANCER, 40(3):333 - 338, Jun. 2003, Peer-reviewed

Presentations

  • Association of polymorphisms in genes encoding immune response-related factors and regorafenib-induced erythema multiforme in patients with advanced colorectal cancer, Geonwoo Lee, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida and Ken-ichi Fujita, 日本薬学会第145年会, 28 Mar. 2025, 日本薬学会, 福岡
  • A polymorphism in ABCC3 is associated with capecitabine-induced hand-foot syndrome and capecitabine pharmacokinetics, Kengo Omata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida3 Ken Shimada, and Ken-ichi Fujita, 2025 the Japanese Society of Medical Oncology Annual Meeting, 06 Mar. 2025
  • Association between ABCC2 -24C>T and nab-paclitaxel-induced peripheral neuropathy in Japanese patients with pancreatic cancer, Hana Nakayama,Hiroo Ishida, Masanori Iidaka, Shoko Kato, Kei Nakatani, Akihiro Nakayama, Toshihiro Noguchi, Shigetoshi Nishihara, Shu Oikawa, Tomono Usami, Yuta Mitsui, Yu Ishii, Hirokazu Toshima, Kouji Kobayashi, Remi Murase, Natsumi Matsumoto, Kosuke Suzuki, Ken Shimada, Hitoshi Yoshida, Ken-ichi Fujita, 2025 the Japanese Society Medical Oncology annual Meeting, 06 Mar. 2025, 日本臨床腫瘍学会, 神戸
  • Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
  • Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
  • Effect of VEGFA and CCL4L2 variants on hand-foot skin reaction and survival of regorafenib in Japanese patients with CRC, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, 2024 the Japanese Society Medical Oncology Annual Meeting, 22 Feb. 2024, Hirogi Iwata, Nagoya Congress Center
  • 高齢者III期NSCLCにCDDP+S-1はPACIFIC戦略の有望レジメンになり得るか?(SAMURAI study探索的解析結果), 岸川 孝之, 丹澤 盛, 田中 寿志, 稲葉 恵, 中村 純也, 中嶌 賢尚, 柴田 和彦, 藤原 慶一, 幸山 正, 石田 博雄, 三角 俊裕, 白石 憲史郎, 松谷 哲行, 関 順彦, 第64回日本肺癌学会学術集会, Oct. 2023
  • Associations of polymorphisms in CCL4L1 with regorafenib-induced hand-foot skin reaction in colorectal cancer patients, Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita, 2023 the Japanese Society of Medical Oncology Annual Meeting. The 20th Anniversary Meeting, 16 Mar. 2023, Japanese Society of Medical Oncology, Fukuoka International Congress Center/ Marine Messe
  • A polymorphisms in ABCA2 is associated with pharmacokinetics and toxicity of capecitabine in colorectal cancer patients, Yukitaka Shibata, Natsumi Matsumoto, Yutaro Kubota, Takuya Tsunoda, Hiroo Ishida, Ken Shimada, Ken-ichi Fujita, The 20th Japanese Society of Medical Oncology annual meeting, 16 Mar. 2023, fukuoka
  • Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07), Hiroo Ishida, Yu Sunakawa, Yasuhiro Kodera, Kazuhiro Yoshida, Mitsugu Kochi, Yoshihiro Kakeji, Takeshi Sano, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, ASCO Gastrointestinal Cancers Symposium 2023, Jan. 2023, San Francisco
  • III期NSCLCにCDDP+S-1はPACIFIC戦略の有望レジメンになり得るか?(SAMURAI study), 藤原 慶一, 丹澤 盛, 田中 寿志, 稲葉 恵, 中村 純也, 岸川 孝之, 中嶌 賢尚, 柴田 和彦, 幸山 正, 石田 博雄, 三角 俊裕, 白石 憲史郎, 松谷 哲行, 関 順彦, 第63回日本肺癌学会学術集会, Oct. 2022
  • Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with colorectal cancer., TAKESHIMA Kousuke;MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;TSUNODA Takuya;SASAKI Yasutsuna;FUJITA Ken-ichi, 123rd American Society for Clinical Pharmacology and Therapeutics annual meeting (accepted)., 16 Mar. 2022, Web
  • Regorafenib-induced erythema multiforme is associated with HLA-C*01:02 and HLA-B*46:01 in Japanese cancer patients, 松本　奈都美;竹島　功高;久保田　祐太郎;石田　博雄;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 18 Feb. 2022, 京都＋Web開催
  • Pharmacokinetics and toxicity of gefitinib in elderly patients with EGFR mutated non-small cell lung cancer, 石田　博雄;仁尾　祐太;松本　奈都美;楠本　壮二郎;久保田　祐太郎;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 17 Feb. 2022, 京都＋Web開催
  • Involvement of BCRP/ABCG2 in gastrointestinal absorption and biliary excretion of a multi-kinase inhibitor pazopanib, YOSHINO Shotaro;MASUO Yusuke;ISHIDA Hiroo;FUJITA Ken-ichi;KATO Yukio, 日本薬物動態学会 第36回年会, 18 Nov. 2021, Web Meeting
  • Assessment and risk control sheet facilitates management in cancer drug therapy, 本間　織重;渡邊　知映;福地本　晴美;柏崎　純子;園生　容子;我妻　志保;細沼　雅弘;久保田　祐太郎;倉増　敦朗;堀池　篤;石田　博雄;嶋田　顕;角田　卓也;梅田　恵;吉村　清, 第59回日本癌治療学会学術集会, 23 Oct. 2021, 横浜・LIVE配信・オンデマンド配信
  • 切除不能局所進行NSCLCに対するCDDP+S-1(SP)化学放射線治療後のDurvalumab(D)維持療法(中間報告), 中村 純也, 丹澤 盛, 田中 寿志, 稲葉 恵, 柴田 和彦, 藤原 慶一, 岸川 孝之, 中嶌 賢尚, 幸山 正, 石田 博雄, 三角 俊裕, 白石 憲史郎, 松谷 哲行, 関 順彦, 第62回日本肺癌学会学術集会, Oct. 2021
  • SN-38の体内動態とOATP1B1の機能:重篤な腎機能障害のない患者において, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第18回日本臨床腫瘍学会学術集会 (JSMO2021), 18 Feb. 2021, オンデマンド配信
  • 抗悪性腫瘍薬イリノテカンの活性代謝物SN-38の体内動態とOATP1B1輸送活性との関連, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第41回日本臨床薬理学会学術総会, 05 Dec. 2020, 福岡およびWeb会場
  • ABCC4遺伝子多型のカペシタビンと代謝物の体内動態への影響, 松本　奈都美;久保田　祐太郎;角田　卓也;石田　博雄;嶋田　顕;増尾　友佑;加藤　将夫;藤田　健一, 第41回日本臨床薬理学会学術総会, 03 Dec. 2020, 福岡およびWeb会場
  • 局所進行NSCLCに対するCDDP+S-1化学放射線治療後のDurvalumab維持療法　Trial in Progress(Samurai Group), 丹澤盛, 牛島淳, 柴田和彦, 柴山卓夫, 別所昭宏, 解良恭一, 三角俊裕, 久山彰一, 宮沢直幹, 中村純也, 幸山正, 中嶌賢尚, 小田尚廣, 田中寿志, 石川暢久, 石田博雄, 笠井尚, 森永亮太郎, 松谷哲行, 関順彦, 第61回日本肺癌学会学術集会, Oct. 2020
  • 脳転移摘出5年後に原発性肺腺癌が診断された1切除例, 山田明子, 坂口浩三, 梅咲徹也, 石田博雄, 田口亮, 柳原章寿, 二反田博之, 石田博徳, 第61回日本肺癌学会学術集会, Oct. 2020
  • EGFR-TKIによって治療されるEGFR変異陽性NSCLC患者における血漿ctDNAを用いた治療モニタリングの観察研究, 木曽原朗, 仲剛, 石田博雄, 岸一馬, 横山琢磨, 上村鋼平, 大橋靖雄, 國頭英夫, 第60回日本呼吸器学会学術講演会, Sep. 2020
  • Treatment choices after recurrence in patients with stage III gastric cancer in JACCRO GC-07 study, Hiroo Ishida, Wataru Ichikawa, Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Yoshihiro Kakeji, Takeshi Sano, Masahiro Takeuchi, Masashi Fujii, 第92回日本胃癌学会総会, Jul. 2020
  • No effects of variants in carboxylesterase 1 gene on pharmacokinetics of capecitabine and its metabolites, 松本　奈都美;久保田　祐太郎;石田　博雄;関戸　匡恵;柴沼　質子;嶋田　顕;藤田　健一, 日本薬学会第140年会, 26 Mar. 2020, Web公開
  • 実臨床でのPD-L1発現検査に関する検討, 楠本　壮二郎;石田　博雄;三浦　咲子;眞鍋　亮;岸野　康成;安藤　浩一;濵田　和幸;山本　滋;大森　亨;瀧本　雅文;武井　秀史;鈴木　隆;角田　卓也;相良　博典, 第60回日本肺癌学会学術集会, 06 Dec. 2019, 大阪
  • ラベプラゾールの併用はカペシタビンと代謝物の体内動態に影響しない, 関戸　匡恵;藤田　健一;久保田　祐太郎;石川　文博;石田　博雄;柴沼　質子;佐々木　康綱, 第17回日本臨床腫瘍学会学術集会, 19 Jul. 2019, 京都
  • Expression of Olfactomedin-4 in pancreatic cancer and its clinical significance, OKUMA Ryotaro;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;TSURUTANI Junji;YOSHIMURA Kiyoshi;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;TSUNODA Takuya;WADA Satoshi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • AUC of unbound form of regorafenib active metabolites M2 and M5 are associated with hand-foot syndrome, and ABCG2 polymorphism in Japanese patients with colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;MASUO Yusuke;ISHIDA Hiroo;KATO Yukio;SASAKI Yasutsuna, 120th American Society for Clinical Pharmacology and Therapeutics annual meeting, 14 Mar. 2019, Washington DC
  • T790M-EGFRによりアファチニブ耐性をきたした肺腺癌細胞株におけるロシレチニブ耐性機序の検討, 山岡　利光;楠本　壮二郎;安藤　浩一;石田　博雄;大西　司;相良　博典;大森　亨, 第59回日本肺癌学会学術集会, 30 Nov. 2018, 東京
  • Assessment of paclitaxel-induced OATP1B inhibition in patients with non-small cell cancer by using endogenous substrates, FUJITA Ken-ichi;MORI Daiki;ISHIDA Hiroo;MIZUNO Tadahaya;MAEDA Kazuya;SASAKI Yasutsuna;KUSUHARA Hiroyuki, 第16回日本臨床腫瘍学会学術集会, 19 Jul. 2018, 神戸
  • ALK陽性を示したSarcomatous Carcinomaの1例, 氷室　直哉;鈴木　隆;新谷　裕美子;南方　孝夫;大島　穣;片岡　大輔;山本　滋;楠本　壮二郎;石田　博雄;田澤　咲子;門倉　光隆, 第58回日本呼吸器学会学術講演会, 28 Apr. 2018, 大阪
  • 内在性基質をプローブとした抗がん剤パクリタキセルによるOATP1B阻害の検出, 森　大輝;石田　博雄;水野　忠快;藤田　健一;楠本　壮二郎;前田　和哉;佐々木　康綱;楠原　洋之, 第38回日本臨床薬理学会学術総会, 09 Dec. 2017, 横浜
  • 有機カチオントランスポーター1はチロシンキナーゼ阻害薬であるパゾパニブの肝取り込みに関与する, 藤田　健一;ELLAWATTY Waleed EA;増尾　友佑;石田　博雄;佐々木　康綱;加藤　将夫, 第38回日本臨床薬理学会学術総会, 08 Dec. 2017, 横浜
  • Assessment of drug-drug interaction potency against OATP1B with paclitaxel using an endogenous substrate as an alternative probe, MORI Daiki;ISHIDA Hiroo;MIZUNO Tadahaya;FUJITA Ken-ichi;KUSUMOTO Sojiro;MAEDA Kazuya;SASAKI Yasutsuna;KUSUHARA Hiroyuki, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
  • 左腕頭静脈合流部への浸潤を疑った縦隔原発脂 肪肉腫の 1 切除例, 山本　滋;新谷　裕美子;南方　孝夫;大島　穣;氷室　直哉;富田　由里;片岡　大輔;楠本　壮二郎;石田　博雄;鈴木　隆;佐々木　康綱;門倉　光隆, 第58回日本肺癌学会学術集会, 14 Oct. 2017, 横浜
  • Organic cation transporter 1 is involved in hepatic uptake of pazopanib in humans, FUJITA Ken-ichi;MASUO Yusuke;ISHIDA Hiroo;SASAKI Yasutsuna;KATO Yukio, 第76回日本癌学会学術総会, 30 Sep. 2017, 横浜
  • Involvement of organic cation transporter 1 in hepatic uptake of pazopanib in humans, ISHIDA Hiroo;ELLAWATTY Waleed Elsayed Ahmed;FUJITA Ken-ichi;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, 第15回日本臨床腫瘍学会学術集会, 27 Jul. 2017, 神戸
  • Dual resistance of EGFR-mutant lung adenocarcinoma cells to EGFR and MET inhibitors, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, 第75回日本癌学会学術総会, 08 Oct. 2016, 横浜
  • Comparison of cancer drug approval by PMDA in the US, SATOH Etsuko;ISHIDA Hiroo;TAKAHASHI Takehiro;KUBOTA Yutaro;KUSUMOTO Sojiro;KISHINO Yasunari;TOJO Masayuki;HAMADA Kazuyuki;SASAKI Yasutsuna, 第14回日本臨床腫瘍学会学術集会, 29 Jul. 2016, 神戸
  • Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡　利光, 第14回日本臨床腫瘍学会学術集会, 28 Jul. 2016, 神戸
  • Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, American Association for Cancer Research Annual Meeting 2016, 18 Apr. 2016, New Orleans
  • UFLC-MS/MS法によるヒト涙液中tegafur及び5-fluorouracilの高感度分析法, 小渕　律子;李　暁鵬;石田　博雄;熊澤　武志;廣澤　槙子;池田　賢一郎;藤城　雅也;藤田　健一;入戸野　晋;小林　一女;佐々木　康綱;高橋　春男;佐藤　啓造, 第62回昭和大学学士会総会, 28 Nov. 2015, 東京
  • Comprehensive analysis of miRNA-variants in Japanese healthy subjects, non-small cell lung carcinoma and colorectal cancer patients, KATAYAMA Koki;GOTOH Saki;FUKAMI Tatsuya;ISHIDA Hiroo;KUBOTA Yutaro;KUSUMOTO Sojiro;FUJITA Ken-ichi;SASAKI Yasutsuna;NAKAJIMA Miki, 日本薬物動態学会第30回年会, 12 Nov. 2015, 東京
  • A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer, FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;TOYA Etsuko;KISHINO Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡　利光;大森　亨;大場　基;外谷　衣都子;岸野　康成;村田　泰規;楠本　壮二郎;石田　博雄;大西　司;相良　博典;佐々木　康綱, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • A clinical pharmacokinetic microdosing study of docetaxel with Japanese cancer patients., FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, The 40th European Society for Medical Oncology Annual Meeting (European Cancer Congress 2015), 27 Sep. 2015, Wien
  • Determination of tegafur and 5-fluorouracil in tear by HILIC-MS/MS., OBUCHI Ritsuko;LEE Xiao-Pen;HIROSAWA Makiko;ISHIDA Hiroo;FUJITA Ken-ichi;NITTONO Susumu;YOSHIDA Masato;SASAKI Yasutsuna;SATO Keizo;TAKAHASHI Haruo, Asia-ARVO (The Association for Research in Vision and Ophtalmology) 2015, 18 Feb. 2015, Yokohama
  • Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with recurrent advanced non-small cell lung cancer., HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, The 39th European Society for Medical Oncology annual meeting, 27 Sep. 2014, Madrid
  • EGFR transactivation by TNF protects EGFR-TKI, gefitinib induced pulmonary injury in SP-C/TNF transgenic mice, YAMAOKA Toshimitsu;OHMORI Tohru;OHKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;HIROSE Takashi;OHNISHI Tsukasa;SASAKI Yasutsuna, 第73回日本癌学会学術総会, 26 Sep. 2014, 横浜
  • TNF transactivation of EGFR protects EGFR-TKI induced pulmonary injury in SPC-TNF transgenic mice, 山岡　利光;外谷　衣都子;大場　基;大木　康成;村田　泰規;楠本　壮二郎;石田　博雄;大森　亨;佐々木　康綱, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
  • 切除不能局所進行肺扁平上皮癌に対するS-1, cisplatin併用化学放射線療法の検討, 石田　博雄;大木　康成;村田　泰規;石田　孔子;楠本　壮二郎;白井　崇生;佐々木　康綱;相良　博典, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • 患者特性によるチオトロピウムの治療効果の差異についての検討, 鈴木　慎太郎;平井　邦朗;神野　恵美;宮田　祐人;山口　宗大;水間　紘子;大木　康成;村田　泰則;本間　哲也;大田　進;山本　真弓;渡部　良雄;石田　博雄;安藤　浩一;白井　崇生;田中　明彦;橋本　直方;横江　琢也;大西　司;相良　博典;福田　充, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • 肥満モデルマウスへの亜硝酸塩の投与による血圧とインスリン感受性に関する検討, 渡部　良雄;横江　琢也;平井　邦朗;宮田　祐人;神野　恵美;水間　紘子;山本　真弓;杉山　智英;山口　宗大;田崎　俊之;大木　康成;村田　泰規;鈴木　慎太郎;石田　博雄;大田　進;白井　崇生;田中　明彦;橋本　直方;大西　司;相良　博典;O’DONNELL Christopher, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • Pharmacokinetics, pharmacogenetics and toxicity of erlotinib in patients with non-small cell lung cancer, 廣瀬　敬;藤田　健一;楠本　壮二郎;白井　崇生;村田　泰則;大木　康成;杉山 　智英;石田　博雄;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;佐々木　康綱;田村　厚久;大田　健, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • 「にんにく卵黄」による薬剤性肺障害が疑われた一例, 鈴木　慎太郎;神野　恵美;宮田　祐人;平井　邦朗;大木　康成;村田　泰規;楠本　壮二郎;石田　博雄;安藤　浩一;白井　崇生;大西　司;相良　博典;斉藤　光次, 第37回日本呼吸器内視鏡学会学術集会, 14 Apr. 2014, 京都
  • 悪性腫瘍による気道狭窄で窒息し放射線照射により救命しえた1例, 村田　泰規;平井　邦朗;神野　恵美;宮田　祐人;山口　宗大;大木　康成;大田　進;渡部　良雄;山本　真弓;楠本　壮二郎;鈴木　慎太郎;石田　博雄;白井　崇生;田中　明彦;横江　琢也;大西　司;相良　博典, 第37回日本呼吸器内視鏡学会学術集会, 14 Apr. 2014, 京都
  • TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice., YAMAOKA Toshimitsu;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;TOYA Etsuko;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 105th American Association for Cancer Research annual meeting, 07 Apr. 2014, San Diego
  • FDG-PETで肺腫瘍が疑われた肺梗塞の一例, 阿久津　靖;金子　堯一;箕浦　慶乃;松井　泰樹;須山　淳平;後閑　武彦;石田　博雄;佐々木　康綱;小林　洋一, 第1回城南Molecular Imaging Conference, 19 Nov. 2013, 東京
  • The characteristics of dual resistance to EGFR & MET inhibitors in pulmonary adenocarcinoma, PC-9 cells, YAMAOKA Toshimitsu;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;OKUDA Kentaro;TOYA Etsuko;OHBA Motoi;OHMORI Tohru;SASAKI Yasutsuna, 第72回日本癌学会学術総会, 03 Oct. 2013, 横浜
  • Clinical benefit of 2nd EGFR-TKI retreatment on overall survival in patients with advanced non-small cell lung cancer, NAKASHIMA Masanao;HIROSE Takashi;OHKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;OKUDA Kentaro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa, 第11回日本臨床腫瘍学会学術集会, 30 Aug. 2013, 仙台
  • The characteristics of an acquired dural resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR, YAMAOKA Toshimitsu;ICHIHASHI Yoko;MURATA Yasunori;OKI Yasunari;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;HIROSE Takashi;OHNISHI Tsukasa;OHMORI Tohru, AACR 104th Annual Meeting 2013, 10 Apr. 2013, Washington, DC
  • Carboplatin+Paclitaxel+Bevacizumabによる化学療法中にIII度房室ブロックをきたした肺腺癌症例, 白井　崇生;廣瀬　敬;大木　康成;村田　泰規;楠本　壮二郎;杉山　智英;石田　博雄;中嶌　賢尚;奥田　健太郎;大西　司;足立　満;山岡　利光;大森　亨, 第53回日本肺癌学会総会, 08 Nov. 2012, 岡山
  • 進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討., 石田　博雄;大木　康成;村田　泰規;石田　孔子;楠本　壮二郎;杉山　智英;白井　崇生;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;廣瀬　敬, 第50回日本癌治療学会学術集会, 25 Oct. 2012, 横浜
  • Cancer vaccination trial novel multiple peptides in previously treated advanced non-small-cell lung cancer (NSCLC), 廣瀬　敬;野田　秀裕;奥田　健太郎;阿部　誠治;大戸　祐治;杉山　智英;石田　博雄;白井　崇生;中嶌　賢尚;山岡　利光;大森　亨;吉田　浩二;中村　祐輔, 第71回日本癌学会学術総会, 19 Sep. 2012, 札幌
  • Cancer Vaccination trial with novel multiple peptides in previously treated advanced non-small cell lung cancer., HIROSE Takashi;NODA Hidehiro;OKUDA Kentaro;ABE Seiji;OTO Yuji;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHMORI Tohru;YOSHIDA Koji;NAKAMURA Yusuke;ADACHI Mitsuru, 2012 Annual Meeting of the American Society of Clinical Oncology, 01 Jun. 2012, Chicago
  • Specific epidermal growth factor receptor autophosphorylation sites promote epithelial cell chemotaxis and restitution., YAMAOKA Toshimitsu;FREY Mark;POLK D Brent;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;OHNISHI Tsukasa;HIROSE Takashi;OHMORI Tohru;ADACHI Mitsuru, AACR 103rd Annual Meeting 2012, 02 Apr. 2012, Chicago

Books etc

  • これだけは押さえておきたい　がん化学療法の薬　抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬　はや調べノート, 分子標的薬　マルチキナーゼ阻害薬　パゾパニブ塩酸塩, 石田博雄, メディカ出版, Mar. 2023
  • 大腸癌化学療法, 大腸癌化学療法におけるキナーゼ阻害薬の位置づけ, 石田博雄、中山博文、市川度, 科学評論社, Jan. 2019

Research Projects

  • パゾパニブの毒性と体内曝露量に関する臨床研究, 石田博雄, 文部科学省, 科学研究費助成事業, 基盤研究（Ｃ）, 16K08918, From 20160401, To 20190331

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.